Status:
Concluded with an LOI
Manufacturer:
AVIR Pharma Inc.
Indication:
Osteoporosis
Last updated September 15, 2021
Status:
Concluded with an LOI
Manufacturer:
Kyowa Kirin Canada, Inc.
Indication:
X-Linked Hypophosphatemia
Last updated September 10, 2021
Vocabria and Cabenuva (cabotegravir and rilpivirine)
Status:
Concluded with an LOI
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 Infection
Last updated September 7, 2021
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Age-Related Macular Degeneration
Last updated August 31, 2021
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Hepatocellular Carcinoma (HCC) in adults after prior therapy
Last updated August 24, 2021
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma
Last updated August 18, 2021
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Metastatic Castration-Sensitive Prostate Cancer
Last updated August 17, 2021
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated August 16, 2021
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Crohn's disease
Last updated August 13, 2021
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Ulcerative Colitis
Last updated August 13, 2021